Literature DB >> 378502

Clinical pharmacokinetics of propranolol.

P A Routledge, D G Shand.   

Abstract

Propranolol is completely absorbed after oral administration and widely distributed throughout tissues. Elimination occurs almost wholly by metabolic transformation in the liver and excretion of the resultant products in the urine. An active metabolite, 4-hydroxypropranolol and possibly other active compounds have been identified; the former only after oral administration. After intravenous administration, hepatic extraction is so efficient that drug clearance is dependent on liver blood flow. After oral administration, propranolol kinetics depend on both dose and duration of therapy, but hepatic extraction remains relatively high and leads in presystemic ('first-pass') elimination and low systemic availability. During continued administration, plasma concentrations vary quite widely due to genetic differences superimposed on which are certain constitutional factors, such as age, and environmental factors such as smoking, other drugs, and perhaps diet. Hepatic, renal, thyroid and some gastrointestinal diseases as well as hypertension, malnutrition and hypothermia may be associated with alterations in propranolol disposition, all of which are consistent with the pathophysiology of these diseases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378502     DOI: 10.2165/00003088-197904020-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  66 in total

1.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Effect of exercise on propranolol pharmacokinetics.

Authors:  S Frank; S M Somani; M Kohnle
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Prescription monitoring of drug dosages in the county of Jämtland and Sweden as a whole in 1976, 1982 and 1985.

Authors:  A Wessling; G Boëthius; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.

Authors:  Marija Tubic-Grozdanis; Michael B Bolger; Peter Langguth
Journal:  AAPS J       Date:  2008-04-02       Impact factor: 4.009

5.  Heart failure in thyrotoxicosis, an approach to management.

Authors:  R P Choudhury; J MacDermot
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

6.  Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.

Authors:  Rachel H Rose; David B Turner; Sibylle Neuhoff; Masoud Jamei
Journal:  AAPS J       Date:  2017-05-19       Impact factor: 4.009

Review 7.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

8.  Propranolol decreases cardiac work in a dose-dependent manner in severely burned children.

Authors:  Felicia N Williams; David N Herndon; Gabriela A Kulp; Marc G Jeschke
Journal:  Surgery       Date:  2011-02       Impact factor: 3.982

9.  Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man.

Authors:  J O Miners; L M Wing; K J Lillywhite; R A Robson
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

Review 10.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.